number PRIMAXIN IV 500 mg/500 mg powder for solution for infusion Zienam 500 mg/500 mg - Pulver zur Herstellung einer Infusionslösung TIENAM 500 mg/500 mg, poudre pour solution pour perfusion TIENAM IV 500 mg + 500 mg Pó para solução para perfusão TIENAM I.V. 500 mg/500 mg milteliai infuziniam tirpalui ТИЕНАМ 500 mg/500 mg прах за инфузионен разтвор TIENAM, 500 mg + 500 mg, proszek do sporządzania roztworu do infuzji TIENAM 500 mg/500 mg poeder voor oplossing voor infusie Tienam 500 mg/500 mg infuusiokuiva-aine, liuosta varten TIENAM I.V. 500 mg/500 mg pulveris infūziju šķīduma pagatavošanai
List of nationally authorised medicinal EMA/88494/2018
NL/H/2160/001
PL 00025/0229
MERCK SHARP & DOHME LTD.
UK
NL/H/2160/001
1-18024
MERCK SHARP & DOHME GES.M.B.H.
AT
NL/H/2160/001
34009 383 370 0 6
MSD FRANCE
FR
NL/H/2160/001
5053376
MERCK SHARP & DOHME, LDA.
PT
NL/H/2160/001
LT/1/93/2969/001
MERCK SHARP & DOHME, UAB
LT
NL/H/2160/001
20020312
MERCK SHARP & DOHME BULGARIA EOOD
BG
NL/H/2160/001
R/0990
MSD POLSKA SP. Z O.O.
PL
NL/H/2160/001
RVG 11089
MERCK SHARP & DOHME BV
NL
NL/H/2160/001
9375
MERCK SHARP & DOHME BV
FI
NL/H/2160/001
93-0495
MERCK SHARP & DOHME LATVIJA SIA
LV
Page 3/5
Product Name (in
MRP/DCP
authorisation country)
Authorisation
National Authorisation Number
MAH of product in the
Member State where
member state
product is authorised
number ZIENAM® 500 mg/500 mg Pulver zur Herstellung einer Infusionslösung Wirkstoffe: Imipenem und Cilastatin TIENAM 500 mg/500 mg por oldatos infúzióhoz PRIMAXIN IV 500 mg/500 mg powder for solution for infusion TIENAM 500 mg/500 mg pulver till infusionsvätska, lösning TIENAM® 500 mg/500 mg, poudre pour solution pour perfusion PRIMAXIN IV 500 mg/500 mg powder for solution for infusion TIENAM 500 mg/500 mg polvere per soluzione per infusione TIENAM® 500 mg/500 mg, poeder voor oplossing voor infusie TIENAM® 500 mg/500 mg, poudre pour solution pour perfusion TIENAM® 500 mg/500 mg i.v. prášek pro infuzní roztok
List of nationally authorised medicinal EMA/88494/2018
Jul 7, 2017 - COMMUNITY MARKETING AUTHORISATIONS AND EXTENSIONS. 2.1. Opinions ... Quality. Rapp: E. Werner .... solutions table with EMA and CVMP responses to the recommendations made by the FishMed Plus. Coalition ...
Jun 22, 2016 - Information Management Division ... This document provides current information related to the volume and evaluation of .... Plasma master file.
Feb 9, 2017 - Notification of discontinuation of a paediatric development which is covered by an agreed ... for the following reason(s): (tick all that apply).
Jul 5, 2017 - Send a question via our website www.ema.europa.eu/contact ... non-proprietary names (INN) and therapeutic areas for all new ... also available in the monthly reports of the Committee for Orphan Medicinal Products (COMP).
Jul 4, 2016 - Send a question via our website www.ema.europa.eu/contact ... non-proprietary names (INN) and therapeutic areas for all new ... also available in the monthly reports of the Committee for Orphan Medicinal Products (COMP).
maximises the chances of a successful marketing authorisation. ... marketing authorisation. ⢠inclusion in the public SME ... E-mail [email protected]. Website ...
Jun 19, 2017 - and may also vary during the course of the review. ...... ViiV Healthcare UK Limited; Treatment of Human Immunodeficiency Virus ..... adjunctive administration of brivaracetam, Treatment of paediatric patients with partial.
5 days ago - Guidelines should include more details on the principles of good information design in which content and layout are ... relevance and importance of the QRD template is also acknowledged in this respect as it is the main tool .... databas
Jun 15, 2016 - Agenda - EMA Human Scientific Committees' Working. Parties with Healthcare Professionals' Organisations. (HCPWP) meeting. 15 June 2016, 08:45hrs to 10:30hrs â meeting room: 3E. Chairs: I. Moulon (EMA) and Gonzalo Calvo (HCPWP). 15 Ju
Feb 7, 2017 - Add an existing Tag to a specific Term . ...... This service creates an email body (text/html) of a user's notification data, a notification is based on.
Feb 9, 2018 - 30 Churchill Place â Canary Wharf â London E14 5EU â United Kingdom. An agency of the European Union ... product information. For information: Summary of opinion. 2.2. Oral explanations and list of outstanding issues. â¢. Product
Oct 23, 2017 - Page 2/61. Table of contents. 1. Introduction. 11. 1.1. Welcome and declarations of interest of members, alternates and experts .......... 11. 1.2. Agenda of the meeting on 23-26 October 2017 . ...... different database to study the ri
Notification of discontinuation of a paediatric development which is covered by an agreed ... for the following reason(s): (tick all that apply). (possible) lack of ...
17 Jan 2018 - Expert meeting on adeno-associated viral vectors, 06 September 2017, EMA, London. CAT: Martina SchüÃler-Lenz. Scope: report of the meeting that took place on 6 September 2017. Action: for adoption. 7.6.3. Environmental assessment of g
Jun 14, 2018 - Page 2/26. Product Name (in authorisation country). MRP/DCP Authorisation number. National Authorisation. Number. MAH of product in the.
Oct 26, 2017 - Injektionssuspension in einer Fertigspritze. Influenza-Impfstoff. (Spaltimpfstoff, inaktiviert, in Zellkulturen hergestellt) not available. BE393556. NANOTHERAPEUTICS. BOHUMIL, S.R.O.. BE. Preflucel injektionsvätska, suspension i för
March 2016 a joint database drug utilisation final study report to the European .... With regards to prescription of CPA/EE for contraceptive management, ...
For a list of RSS readers please refer to our RSS guide and follow the instructions ..... PCWP and HCPWP joint meeting: Workshop on social media - Sep 2016.
Jul 14, 2016 - Stem cell-based products for veterinary use: specific ... potentially delay time to rejection providing a window of therapeutic benefit but limiting ...
